cardiometabolic disease

Zug, Switzerland & Boston, Mass. – August 28, 2026 CRISPR Therapeutics presented new Phase 1a durability data for CTX310,...

HEIDELBERG, Germany — August 25, 2026 Revier Therapeutics has officially launched operations following the closing of a €6 million...

Cambridge, Massachusetts, August 10, 2026 Ernexa Therapeutics announced the appointment of David Polinsky to its Board of Directors as...

Vancouver, British Columbia, August 11, 2026 Genome BC has announced six research projects supported through its Data Access, Integration...

Miami, Florida, August 10, 2026 Veru Inc. has announced full enrollment of 239 patients in its Phase 2b PLATEAU...

MIAMI, Fla., July 27, 2026 Veru Inc. announced the successful completion of patient enrollment in its Phase 2b PLATEAU...

WATERTOWN, Mass., July 27, 2026 Neumora Therapeutics announced positive preclinical toxicology results for NMRA-215, its investigational brain-penetrant oral NLRP3...

RAMAT-GAN, Israel, July 16, 2026 Galmed Pharmaceuticals Ltd. has announced the breakthrough development of a novel lipid nanoparticle (LNP)...

INGELHEIM, Germany, July 16, 2026 Boehringer Ingelheim has initiated a Phase II clinical trial evaluating BI 3034701, an investigational...

CAMBRIDGE, Mass. | July 9, 2026 MetaVia Inc., a clinical-stage biotechnology company focused on developing innovative therapies for cardiometabolic...